Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Other Accumulated Expenses (2019 - 2025)

Nurix Therapeutics (NRIX) has disclosed Other Accumulated Expenses for 7 consecutive years, with $2.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Accumulated Expenses fell 7.87% to $2.1 million in Q4 2025 year-over-year; TTM through Nov 2025 was $2.1 million, a 7.87% decrease, with the full-year FY2025 number at $2.1 million, down 7.87% from a year prior.
  • Other Accumulated Expenses was $2.1 million for Q4 2025 at Nurix Therapeutics, up from $1.7 million in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $2.7 million in Q1 2025 to a low of $551000.0 in Q1 2022.
  • A 5-year average of $1.3 million and a median of $927000.0 in 2023 define the central range for Other Accumulated Expenses.
  • Peak YoY movement for Other Accumulated Expenses: skyrocketed 272.71% in 2022, then crashed 50.03% in 2023.
  • Nurix Therapeutics' Other Accumulated Expenses stood at $628000.0 in 2021, then soared by 139.33% to $1.5 million in 2022, then plummeted by 50.03% to $751000.0 in 2023, then skyrocketed by 202.93% to $2.3 million in 2024, then decreased by 7.87% to $2.1 million in 2025.
  • Per Business Quant, the three most recent readings for NRIX's Other Accumulated Expenses are $2.1 million (Q4 2025), $1.7 million (Q3 2025), and $1.0 million (Q2 2025).